adMare
News

News - Thumbnail

November 28 2023

adMare BioInnovations Welcomes 22 Influential Life Sciences Leaders to Cohort VI of the adMare Academy Executive Institute 

 

Read
News - Thumbnail

November 27 2023

CASTL Opens Biomanufacturing Training Facility in Quebec

 

Read
News - Thumbnail

November 21 2023

The adMare Institute Examines the Critical Role of Anchor Companies in Building Globally Competitive Life Sciences Innovation Ecosystems 

Read
News - Thumbnail

November 08 2023

Thryv Therapeutics Presents Benefits of Therapeutic SGK1 Inhibition with THRV-1268 in a Murine Model of Atrial Fibrillation at American Heart Association Scientific Sessions

Read
News - Thumbnail

October 23 2023

adMare BioInnovations Launches the Refreshed Version of the adMare Community with New Engaging Features

Read
News - Thumbnail

October 11 2023

adMare BioInnovations and MaRS Discovery District Welcome Inaugural Ontario Start-Ups to Therapeutics Accelerator Program

Read
News - Thumbnail

October 10 2023

Specific Biologics Announces Additional Investment and Appointment of Experienced Biotechnology Leader Steven Kanner, PhD, to the Board of Directors

Read
News - Thumbnail

October 04 2023

adMare BioInnovations Appoints John DeLucchi, Martin LeBlanc, and Tim van Biesen to the Board of Directors

Read
News - Thumbnail

September 25 2023

Zucara Therapeutics Doses First Patient in Phase 2a ‘ZONE’ Trial

– ZONE study to evaluate the effect of ZT-01 on preventing nighttime hypoglycemia in people with Type 1 diabetes –

– ZT-01 has the potential to become the first therapeutic to prevent nocturnal hypoglycemia, a condition for which there are currently no available therapies –

Read
News - Thumbnail

August 25 2023

Thryv Therapeutics Announces Positive Results from the WAVE 1 Proof of Concept Study.

Read
News - Thumbnail

August 24 2023

adMare BioInnovations invites early-career science professionals to apply to the BioInnovation Scientist (BIS) Program: Foundations Cohort II

 

Read
News - Thumbnail

August 15 2023

Thryv Therapeutics announces FDA clearance for Phase 1 Study of THRV-1257 in Anaplastic Thyroid Cancer and acceptance of Late-Breaking Poster Presentation at American Thyroid Association Meeting.

 

Read